Paul Schmidt, MD
Family Medicine · Glen Rose, TXNPI 1073516704
Payments from drug & device makers
Across 232 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$599
- AstraZeneca$394
- Exact Sciences$280
- Amgen$264
- Lilly USA, LLC$261
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,591100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,117 |
| Supernus Pharmaceuticals, Inc. | 20 | $599 |
| AstraZeneca | 14 | $394 |
| Exact Sciences | 14 | $280 |
| Amgen | 15 | $264 |
| Lilly USA, LLC | 13 | $261 |
| Novo Nordisk | 13 | $199 |
| Otsuka America Pharmaceutical, Inc. | 9 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $154 |
| Johnson & Johnson(2 entities) | 3 | $149 |
| Pfizer | 5 | $93 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Abbott | 5 | $84 |
| GSK | 1 | $83 |
| Bayer | 4 | $67 |
| Astellas Pharma US Inc | 2 | $57 |
| Antares Pharma, Inc. | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 4 | $55 |
| Dexcom, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Merck | 2 | $32 |
| Corium, LLC | 1 | $28 |
| Alfasigma USA, Inc. | 2 | $26 |
| IBSA Pharma Inc. | 1 | $25 |
| Mycovia Pharmaceuticals, Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
| Halozyme Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,611 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 222 | $243,262 |
| EliquisApixaban | 203 | $183,689 |
| JardianceEmpagliflozin | 169 | $133,061 |
| TrulicityDulaglutide | 64 | $86,416 |
| OzempicSemaglutide | 83 | $81,728 |
| XareltoRivaroxaban | 111 | $79,055 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $43,791 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $34,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $33,425 |
| VraylarCariprazine Hcl | 15 | $25,531 |
| FarxigaDapagliflozin Propanediol | 31 | $23,781 |
| Nurtec OdtRimegepant Sulfate | 13 | $19,728 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 661 | $18,011 |
| JanuviaSitagliptin Phosphate | 20 | $17,988 |
| RybelsusSemaglutide | 16 | $16,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $261 | $329,678286 claims |
| PfizerEliquis, Nurtec Odt | $93 | $203,418216 claims |
| Novo NordiskOzempic, Rybelsus | $199 | $98,62499 claims |
| Johnson & JohnsonXarelto | $149 | $79,055111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $83 | $66,837136 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $394 | $64,017109 claims |
| AbbVieVraylar, Linzess | $1,117 | $39,61732 claims |
| MerckJanuvia | $32 | $17,98820 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $10,25411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Glen Rose
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.